加载中
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
前收盘价
US$9.81
+US$0.31 · +3.26%
盘后
US$9.81
US$0.00 · 0.00%
10月7日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
日内区间
当前US$9.81
52周区间
当前US$9.81
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
88
深度低估
情绪
72
看涨
风险
39
中等风险
动量
71
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
日内区间
当前US$9.81
52周区间
当前US$9.81
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2.28亿 USD | 2.3亿 USD | 2.36亿 USD | 2.28亿 USD | 2.53亿 USD |
| 销货成本 | 5815.7万 USD | 6440.4万 USD | 6268.2万 USD | 5509.3万 USD | 6370.1万 USD |
| 毛利 | 1.7亿 USD | 1.66亿 USD | 1.73亿 USD | 1.73亿 USD | 1.89亿 USD |
| 研究与开发 | 6206.8万 USD | 5493.5万 USD | 5038.2万 USD | 5224万 USD | 7187万 USD |
| 销售、一般及管理费用 | 7120.9万 USD | 8016.3万 USD | 8930.8万 USD | 8997.8万 USD | 1.16亿 USD |
| 营业费用 | 1.33亿 USD | 1.35亿 USD | 1.4亿 USD | 1.49亿 USD | 1.88亿 USD |
| 利息收入 | 407.8万 USD | 472.4万 USD | 260.5万 USD | 81.3万 USD | 16万 USD |
| 利息支出 | 662.2万 USD | 1245.2万 USD | 1333万 USD | 1159.2万 USD | 1280.7万 USD |
| 折旧和摊销 | 1093.8万 USD | 1152.4万 USD | 1151.9万 USD | 984万 USD | 1130.5万 USD |
| 营业利润 | 3729.9万 USD | 3096.6万 USD | 3264万 USD | 2372万 USD | 129万 USD |
| 净利润 | 3111.1万 USD | 3027.8万 USD | 2159.1万 USD | 2000 USD | −2912.6万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Avantis U.S. Small Cap Value ETFAVUV2277.31万0.07%308.62亿 USD0.25%US$119.13-1.11%
Vanguard Morningstar Total Stock Market ETFVTI1223.58万0.00%2.3万亿 USD0.03%US$381.03-0.40%
iShares Russell 2000 ETFIWM1131.42万0.01%785.63亿 USD0.19%US$277.7-1.29%
Vanguard Extended Market ETFVXF418.73万0.00%954亿 USD0.05%US$233.49-1.56%
Dimensional - US Targeted Value ETFDFAT378.98万0.01%300.02亿 USD0.33%US$67.08-1.29%
Dimensional - US Small Cap ETFDFAS371.68万0.01%336.6亿 USD0.31%US$77.92-1.38%
EA Bridgeway Omni Small-Cap Value ETFBSVO241万0.10%23.74亿 USD0.45%US$28.29-0.90%
Vanguard Russell 2000 ETFVTWO231.8万0.01%180亿 USD0.06%US$112.21-1.26%Avantis U.S. Small Cap Value ETFAVUVVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFDimensional - US Targeted Value ETFDFATDimensional - US Small Cap ETFDFASEA Bridgeway Omni Small-Cap Value ETFBSVOVanguard Russell 2000 ETFVTWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
